Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sanjay Popat

Showing results (101-110 of 272) with videos related to

Pageof 28
Sort By:
JTO Clinical and Research Reports|August 2, 2024
Successful Lorlatinib Rechallenge After Severe Drug-Induced Psychosis in ALK-Positive Metastatic NSCLC: A Case ReportAlexius John, Joanna Vick, Sarah Sarker, et al.
Lung Cancer (Amsterdam, Netherlands)|December 13, 2006
Recurrent responses to non-small cell lung cancer brain metastases with erlotinibSanjay Popat, Sarah Hughes, Panos Papadopoulos, et al.
Journal of Telemedicine and Telecare|April 26, 2013
A pilot study of a novel home telemonitoring system for oncology patients receiving chemotherapyKofi Nimako, Shir-Kiong Lu, Bee Ayite, et al.
Chinese Medical Journal|March 3, 2011
Mismatch repair, minichromosome maintenance complex component 2, cyclin A, and transforming growth factor β receptor type II as prognostic factors for colorectal cancer: results of a 10-year prospective study using tissue microarray analysisDong-bing Zhao, Ian Chandler, Zheng-ming Chen, et al.
JAMA Network Open|May 25, 2022
Association Between Smoking History and Overall Survival in Patients Receiving Pembrolizumab for First-Line Treatment of Advanced Non-Small Cell Lung CancerSanjay Popat, Stephen V Liu, Nicolas Scheuer, et al.
JTO Clinical and Research Reports|November 24, 2025
Risk Factors Associated With Incidence of Lung Cancer in Never-Smokers: A Systematic Review and Meta-AnalysisSindhu Bhaarrati Naidu, Allegra Wisking, Akul Karoshi, et al.
JCO Precision Oncology|January 7, 2022
Durable Response to Vismodegib in PTCH1 F1147fs Mutant Relapsed Malignant Pleural Mesothelioma: Implications for Mesothelioma Drug TreatmentSanjay Popat, Bhupinder Sharma, Suzanne MacMahon, et al.
Lung Cancer (Amsterdam, Netherlands)|August 23, 2011
ALK translocation is associated with ALK immunoreactivity and extensive signet-ring morphology in primary lung adenocarcinomaSanjay Popat, David Gonzalez, Toon Min, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 21, 2010
Modest reductions in dose intensity and drug-induced neutropenia have no major impact on survival of patients with non-small cell lung cancer treated with platinum-doublet chemotherapyAndre T Brunetto, Craig P Carden, James Myerson, et al.
Nature Communications|June 17, 2022
Addressing challenges with real-world synthetic control arms to demonstrate the comparative effectiveness of Pralsetinib in non-small cell lung cancerSanjay Popat, Stephen V Liu, Nicolas Scheuer, et al.
Pageof 28

Showing results (101-110 of 272) with videos related to

Sort By:
Pageof 28
JTO Clinical and Research Reports|August 2, 2024
Successful Lorlatinib Rechallenge After Severe Drug-Induced Psychosis in ALK-Positive Metastatic NSCLC: A Case ReportAlexius John, Joanna Vick, Sarah Sarker, et al.
Lung Cancer (Amsterdam, Netherlands)|December 13, 2006
Recurrent responses to non-small cell lung cancer brain metastases with erlotinibSanjay Popat, Sarah Hughes, Panos Papadopoulos, et al.
Journal of Telemedicine and Telecare|April 26, 2013
A pilot study of a novel home telemonitoring system for oncology patients receiving chemotherapyKofi Nimako, Shir-Kiong Lu, Bee Ayite, et al.
Chinese Medical Journal|March 3, 2011
Mismatch repair, minichromosome maintenance complex component 2, cyclin A, and transforming growth factor β receptor type II as prognostic factors for colorectal cancer: results of a 10-year prospective study using tissue microarray analysisDong-bing Zhao, Ian Chandler, Zheng-ming Chen, et al.
JAMA Network Open|May 25, 2022
Association Between Smoking History and Overall Survival in Patients Receiving Pembrolizumab for First-Line Treatment of Advanced Non-Small Cell Lung CancerSanjay Popat, Stephen V Liu, Nicolas Scheuer, et al.
JTO Clinical and Research Reports|November 24, 2025
Risk Factors Associated With Incidence of Lung Cancer in Never-Smokers: A Systematic Review and Meta-AnalysisSindhu Bhaarrati Naidu, Allegra Wisking, Akul Karoshi, et al.
JCO Precision Oncology|January 7, 2022
Durable Response to Vismodegib in PTCH1 F1147fs Mutant Relapsed Malignant Pleural Mesothelioma: Implications for Mesothelioma Drug TreatmentSanjay Popat, Bhupinder Sharma, Suzanne MacMahon, et al.
Lung Cancer (Amsterdam, Netherlands)|August 23, 2011
ALK translocation is associated with ALK immunoreactivity and extensive signet-ring morphology in primary lung adenocarcinomaSanjay Popat, David Gonzalez, Toon Min, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 21, 2010
Modest reductions in dose intensity and drug-induced neutropenia have no major impact on survival of patients with non-small cell lung cancer treated with platinum-doublet chemotherapyAndre T Brunetto, Craig P Carden, James Myerson, et al.
Nature Communications|June 17, 2022
Addressing challenges with real-world synthetic control arms to demonstrate the comparative effectiveness of Pralsetinib in non-small cell lung cancerSanjay Popat, Stephen V Liu, Nicolas Scheuer, et al.
Pageof 28